1 Study Matches
Site for A Phase III Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK7339-013)
This is a Phase 3 Study of the study drug Pembro in combination with chemoradiation followed by Pembro alone or with a combination of Pembro/Olaparib in subjects without prior treatment of Limited Stage Small Cell Lung Cancer.
18 year(s) or older
Inclusion Criteria:Has pathologically (histologically or cytologically) confirmed SCLC.
Has LS-SCLC (Stage I-III, by AJCC 8th Edition Cancer Staging), and can be safely treated with definitive radiation doses.
Has no evidence of metastatic disease by whole body PET/CT scan, CT or MRI scans of diagnostic quality of chest, abdomen, pelvis and brain.
Has not received prior treatment (chemotherapy or radiotherapy or surgery resection) of LS-SCLC.
Has ECOG Performance score 0 or 1 assessed within 7 days prior to the first administration of study intervention.
Exclusion Criteria:Has history, current diagnosis, or features suggestive of MDS/AML.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
Has received prior therapy with olaparib or with any other PARP inhibitor.
Had major surgery <4 weeks prior to the first dose of study intervention
Has received colony-stimulating factors 28 days prior to the first dose of study intervention.